Cancers, Vol. 12, Pages 813: Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme
In conclusion, ensartinib may perpetrate clinically relevant pharmacokinetic DDIs and modulate ABCB1-, ABCG2-, and CYP3A4-mediated MDR. The in vitro findings presented here will provide a valuable foundation for future in vivo investigations.
Source: Cancers - Category: Cancer & Oncology Authors: Vagiannis Novotna Skarka Kammerer K üpper Chen Guo Staud Hofman Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Docetaxel | Lung Cancer | Multidrug Resistance | Non-Small Cell Lung Cancer | Study | Taxotere | Urology & Nephrology